Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Gemcitabine; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 12 May 2018 Results (n=64) assessing the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors, were published in the Investigational New Drugs.
    • 09 Apr 2018 Planned End Date changed from 28 Mar 2018 to 14 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top